Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Motorola Solutions Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Motorola Solutions Inc trades at $424.88 (market cap $70.20B). The key difference: Motorola Solutions Inc is the larger of the two by market cap, and Motorola Solutions Inc pays a 1.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MSI | |
|---|---|---|
Market Cap | $39.89B | $70.20B |
Sector | Health | Technology |
52-Week High | $491.22 | $490.30 |
52-Week Low | $278.09 | $363.83 |
Enterprise Value | $38.15B | $78.90B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Motorola Solutions (MSI) trades at $422.88, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $3.37 versus $3.24 expected, and a robust net income margin of 17.61%. Recent news highlights AI expansion in public safety, including the $1.5 billion acquisition of D-Fend Solutions, enhancing its competitive edge in counter-drone technology.
Outlook remains positive with a consensus price target of $512.33, indicating 21% upside. Risks include high valuation multiples like a P/E of 34.1 and increased debt from acquisitions. The company's focus on mission-critical AI and a $15.7 billion backlog supports growth, but investors should monitor integration execution and macroeconomic pressures on public spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
